Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on July 20, 2015. The filing discloses an amendment to the employment agreement of Marina Hahn, President, Consumer, effective July 1, 2015.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments.
Material Changes
- Base Salary Increase: Ms. Hahn's annual base salary was increased to $375,000.
- Bonus Potential: Target bonus potential was increased to 50% of her adjusted annual salary.
- Equity Grant: The Company agreed to grant an option to purchase 150,000 shares of Common Stock at the closing price on the grant date.
- Vesting Terms: Vesting is based on performance criteria (confidential). Full acceleration of 100% of the option occurs if Ms. Hahn is terminated without Cause or resigns for Good Reason within 30 days prior to and 12 months following a Change in Control.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or general risk factors. The primary contingency noted is the acceleration of equity vesting in the event of a Change in Control combined with specific termination or resignation scenarios.
Investor Verification Checklist
- Verify the exact performance criteria for the 150,000 share option grant, as the filing states these are confidential.
- Review the full Amendment document when filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2015.
- Confirm the specific grant date to determine the exercise price per share.
- Note the discrepancy between the requested company name (Decoy Therapeutics) and the filing registrant (Flex Pharma, Inc.).